RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
RetinalGenix Technologies (OTCQB:RTGN) has announced significant advancements in its patent portfolio for home and remote health monitoring technology. The company received approval for U.S. Patent Application No. 2024/0099581 Al, which focuses on expanded peripheral retina mapping crucial for early detection of diseases like diabetes and Alzheimer's.
The company's technology combines high-resolution retinal imaging with their proprietary DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, enabling 24/7 real-time health monitoring and early disease detection. The system is designed for deployment across various settings including homes, clinics, and nursing homes, potentially reducing office visits and streamlining care workflows.
RetinalGenix Technologies (OTCQB:RTGN) ha annunciato significativi progressi nel suo portafoglio di brevetti per la tecnologia di monitoraggio sanitario domestico e a distanza. L'azienda ha ricevuto l'approvazione per US Patent Application No. 2024/0099581 A1, che si concentra sull'espansione della mappatura della retina periferica, cruciale per l'identificazione precoce di malattie come il diabete e l'Alzheimer.
La tecnologia dell'azienda combina un'imaging retinale ad alta risoluzione con la loro piattaforma proprietaria DNA/RNA/GPS Pharmaco-Genetic Mapping™, consentendo un monitoraggio della salute in tempo reale 24/7 e una rilevazione precoce delle malattie. Il sistema è progettato per essere impiegato in diversi contesti tra cui case, cliniche e centri di assistenza, con potenziale per ridurre le visite ambulatorie e snellire i flussi di lavoro sanitari.
RetinalGenix Technologies (OTCQB:RTGN) ha anunciado avances significativos en su cartera de patentes para tecnología de monitoreo de salud en casa y a distancia. La empresa obtuvo la aprobación de US Patent Application No. 2024/0099581 A1, que se centra en una ampliada cartografía de la retina periférica, crucial para la detección temprana de enfermedades como la diabetes y el Alzheimer.
La tecnología de la empresa combina imagen de retina de alta resolución con su plataforma propietaria DNA/RNA/GPS Pharmaco-Genetic Mapping™, permitiendo un monitoreo de salud en tiempo real las 24 horas y la detección temprana de enfermedades. El sistema está diseñado para su implementación en diversos entornos, incluidos hogares, clínicas y hogares de ancianos, con potencial para reducir visitas al consultorio y optimizar los flujos de atención.
RetinalGenix Technologies (OTCQB:RTGN)가 가정 및 원격 건강 모니터링 기술에 대한 특허 포트폴리오에서 상당한 발전을 발표했습니다. 회사는 미국 특허 출원번호 2024/0099581 A1의 승인을 받았으며, 이는 당뇨병과 알츠하이머와 같은 질병의 조기 발견에 결정적인 말초 망막 매핑의 확장에 초점을 맞춥니다.
회사의 기술은 고해상도 망막 영상과 독점적인 DNA/RNA/GPS Pharmaco-Genetic Mapping™ 플랫폼을 결합하여 24시간 365일 실시간 건강 모니터링 및 조기 질병 탐지를 가능하게 합니다. 이 시스템은 가정, 클리닉, 요양원 등 다양한 환경에서 배치되도록 설계되었으며, 진료 방문을 줄이고 간호 흐름을 간소화할 수 있습니다.
RetinalGenix Technologies (OTCQB:RTGN) a annoncé des avancées significatives dans son portefeuille de brevets pour la technologie de surveillance de la santé à domicile et à distance. La société a obtenu l'approbation de US Patent Application No. 2024/0099581 A1, qui se concentre sur une cartographie étendue de la rétine périphérique, cruciale pour le dépistage précoce de maladies comme le diabète et Alzheimer.
La technologie de la société combine une imagerie rétinienne haute résolution avec leur plateforme propriétaire DNA/RNA/GPS Pharmaco-Genetic Mapping™, permettant une surveillance de la santé en temps réel 24/7 et une détection précoce des maladies. Le système est conçu pour être déployé dans divers environnements, notamment à domicile, en clinique et dans les maisons de retraite, ce qui pourrait réduire les visites chez le médecin et rationaliser les flux de travail des soins.
RetinalGenix Technologies (OTCQB:RTGN) hat bedeutende Fortschritte in seinem Patentportfolio für Heim- und Fernüberwachungstechnologie angekündigt. Das Unternehmen erhielt die Zulassung für US Patent Application No. 2024/0099581 A1, das sich auf eine erweiterte periphere Netzhautkartierung konzentriert, die für die frühzeitige Erkennung von Krankheiten wie Diabetes und Alzheimer entscheidend ist.
Die Technologie des Unternehmens kombiniert hochauflösende Netzhautbildgebung mit ihrer firmeneigenen DNA/RNA/GPS Pharmaco-Genetic Mapping™-Plattform, die eine 24/7 Echtzeit-Gesundheitsüberwachung und frühzeitige Krankheitserkennung ermöglicht. Das System ist für den Einsatz in verschiedenen Umgebungen konzipiert, darunter zu Hause, Kliniken und Pflegeheime, und könnte Arztbesuche reduzieren und Arbeitsabläufe in der Versorgung rationalisieren.
أعلنت شركة RetinalGenix Technologies (OTCQB:RTGN) عن تقدم كبير في محفظة براءات الاختراع الخاصة بها لتقنية المراقبة الصحية في المنزل وعن بُعد. حصلت الشركة على موافقة على US Patent Application No. 2024/0099581 A1، والتي تركز على توسيع خريطة الشبكية المحيطية الضرورية للكشف المبكر عن أمراض مثل السكري ومرض الزهايمر.
تقنية الشركة تجمع بين تصوير الشبكية عالي الدقة مع منصتها الحاصلة على الملكية DNA/RNA/GPS Pharmaco-Genetic Mapping™، مما يتيح المراقبة الصحية في الوقت الحقيقي على مدار 24 ساعة وكشف مبكر عن الأمراض. النظام مصمم للنشر عبر إعدادات متعددة بما في ذلك المنازل والعيادات ودور المسنين، مما قد يقلل من زيارات المكاتب ويرتب سير عمل الرعاية الصحية.
RetinalGenix Technologies (OTCQB:RTGN) 已宣布在家庭与远程健康监测技术的专利组合方面取得重大进展。公司已获得 美国专利申请号 2024/0099581 A1 的批准，关注扩展周边视网膜映射，对糖尿病和阿尔茨海默病等疾病的早期检测至关重要。
公司技术将 高分辨率视网膜成像 与其专有的 DNA/RNA/GPS Pharmaco-Genetic Mapping™ 平台 相结合，实现 24/7 实时健康监测与早期疾病检测。该系统设计用于在家庭、诊所和护理院等多种环境中部署，可能减少门诊就诊并简化护理工作流程。
- None.
- Company still in developmental stage with no current commercialization
- No immediate revenue generation from patent portfolio
- Implementation timeline and regulatory approval status not specified
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage ophthalmic monitoring and biopharmaceutical company focused on early detection and treatments for eye and systemic diseases, is proud to announce significant advancements in its patent portfolio, helping to position it at the forefront of home and remote health monitoring for ocular and systemic diseases.
Recently granted patents, including U.S. Patent Application No. 2024/0099581 Al, cover key aspects of real-time home and remote ocular monitoring and scalable physician alert systems.
The current patent, filed in 2023 and approved after three years, focuses on the need to expand the mapping of the peripheral retina. This mapping is crucial for identifying various diseases, including the earliest retinal changes associated with diabetes. Additionally, it includes biomarkers such as beta-amyloid protein, which is linked to Alzheimer's disease and other disorders. This patent enhances the Company’s already strong diagnostic capabilities, which involve assessing any ocular structure and enabling home monitoring, by integrating the expanded mapping of the retinal landscape. These patents provide foundational protection for both the hardware and workflow involved in these technologies. They enable high-resolution retinal imaging to be conducted in the home and remotely, offering real-time alerts and facilitating early-stage disease detection for patients and healthcare providers, regardless of their location.
RetinalGenix’s proprietary DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, along with its related test kits, is planned to integrate with the Company’s high-resolution retinal imaging system. This combination is designed to empower both patients and clinicians with actionable biomarker information, facilitating rapid clinical triage. Ultimately, the goal is to reduce the frequency of office visits and streamline critical care workflows. These systems are intended for widespread deployment across various settings, including homes, clinics, urgent care centers, nursing homes, and more.
Jerry Katzman, MD, CEO of RetinalGenix, stated: “Our patented remote monitoring system is expected to revolutionize both eye care and systemic disease detection. Our cutting-edge technology is intended to allow patients and physicians to gain 24/7, real-time access to health data, enabling early intervention and supporting new models of care. We believe we are leading a paradigm shift toward accessible, affordable, and patient-centered diagnostics and screening.”
RetinalGenix patents are among the industry’s broadest, providing strong protection for device, system, and digital workflow innovations. This intellectual property portfolio sets the Company apart and is expected to position it for new partnerships, licensing, and expansion.
These patent achievements directly benefit RetinalGenix shareholders by securing exclusive commercialization rights, enhancing strategic competitive advantage, and helping to expand opportunities for partnership and revenue generation in the fast-growing telemedicine, ophthalmology, and healthcare technology sectors.
For media inquiries and investor relations, please contact:
RetinalGenix Technologies Investor Relations
T: 800-331-5446
IR@retinalgenix.com
About RetinalGenix Technologies Inc.
RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding positioning the Company at the forefront of home and remote health monitoring for ocular and systemic diseases, integrating RetinalGenix’s DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, along with its related test kits, with its high-resolution retinal imaging system, the combination empowering both patients and clinicians with actionable biomarker information, facilitating rapid clinical triage, reducing the frequency of office visits and streamlining critical care workflows, deploying the systems across various settings, including homes, clinics, urgent care centers, nursing homes, and more, the Company’s patented remote monitoring system revolutionizing both eye care and systemic disease detection, providing patients and physicians 24/7, real-time access to health data, enabling early intervention and supporting new models of care, leading a paradigm shift toward accessible, affordable, and patient-centered diagnostics and screening, RetinalGenix patents providing strong protection for device, system, and digital workflow innovations, being positioned it for new partnerships, licensing, and expansion and expanding opportunities for partnership and revenue generation in the fast-growing telemedicine, ophthalmology, and healthcare technology sectors. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to deploy its the systems across various settings, including homes, clinics, urgent care centers and nursing homes, the Company’s ability to revolutionize both eye care and systemic disease detection, the Company’s ability to enter into new partnerships and licensing arrangements, the Company’s ability to generate revenue, the Company’s ability to protect its intellectual property and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Media Contact:
For further information, please contact:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
FAQ
What new patent did RetinalGenix (RTGN) receive in 2025?
How does RetinalGenix's remote monitoring system work?
Where can RetinalGenix's monitoring system be deployed?
What diseases can RetinalGenix's technology detect?
How does this patent advancement benefit RTGN shareholders?
